Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 9/2007

01-09-2007 | Review Article

Drug-Induced Cardiovascular Disorders

Authors: Dr C. Aengus Murphy, Henry J. Dargie

Published in: Drug Safety | Issue 9/2007

Login to get access

Abstract

As the variety and range of pharmaceutical agents available to the medical profession continues to expand, one unavoidable effect will be an increase in drug-induced disease, including cardiovascular disorders. However, given the high rates of cardiovascular disease and prevalence of recognised cardiovascular risk factors in the population, it is sometimes impossible to conclusively attribute any individual patients’ ill health to one particular drug. As a result, the relationship between drugs and cardiovascular disease is often difficult to quantify. This review discusses specific forms of drug-induced cardiovascular disease such as heart failure, left ventricular systolic dysfunction, hypertension and arrhythmia. Suspected culprit drugs for all disorders are highlighted. Specific attention is given to certain drug groups with a strong association with one or more forms of cardiovascular disease: these include anthracyclines, antipsychotics, NSAIDs and cyclo-oxygenase 2 inhibitors. Additionally, advice is offered on how physicians might distinguish drug-induced cardiovascular disorders from other aetiologies.
Literature
1.
McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997 Sep 20; 350(9081): 829–33PubMedCrossRef
2.
Berry C, Hogg K, Norrie J, et al. Heart failure with preserved left ventricular systolic function: a hospital cohort study. Heart 2005 Jul; 91(7): 907–13PubMedCrossRef
3.
Cleland JG, Swedberg K, Cohen-Solal A, et al. The Euro Heart Failure Survey of the EUROHEART survey programme: a survey on the quality of care among patients with heart failure in Europe. The Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The Medicines Evaluation Group Centre for Health Economics University of York. Eur J Heart Fail 2000 Jun; 2(2): 123–32PubMedCrossRef
4.
Schocken DD, Arrieta MI, Leaverton PE, et al. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992 Aug; 20(2): 301–6PubMedCrossRef
5.
Ghalie RG, Edan G, Laurent M, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002 Sep 24; 59(6): 909–13PubMedCrossRef
6.
Schimmel KJ, Richel DJ, van den Brink, et al. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004; 30: 181–91PubMedCrossRef
7.
Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995 Nov; 13(11): 2688–99PubMed
8.
Brakoulias V, Bannan E, Cohen P, et al. Amisulpride and cardiomyopathy. Aust N Z J Psychiatry 2005 Aug; 39(8): 738PubMed
9.
Coulter DM, Bate A, Meyboom RH, et al. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ 2001 May 19; 322(7296): 1207–9PubMedCrossRef
10.
Roesch-Ely D, Van Einsiedel R, Kathofer S, et al. Myocarditis with quetiapine. Am J Psychiatry 2002 Sep; 159(9): 1607–8PubMedCrossRef
11.
Killian JG, Kerr K, Lawrence C, et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999 Nov 27; 354(9193): 1841–5CrossRef
12.
La Grenade L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med 2001 Jul 19; 345(3): 224–5PubMedCrossRef
13.
Hagg S, Spigset O, Bate A, et al. Myocarditis related to clozapine treatment. J Clin Psychopharmacol 2001 Aug; 21(4): 382–8PubMedCrossRef
14.
Lucas CM, Cheriex EC, van der Veen FH, et al. Imipramine induced heart failure in the dog: a model to study the effect of cardiac assist devices. Cardiovasc Res 1992 Aug; 26(8): 804–9PubMedCrossRef
15.
Faisy C, Guerot E, Diehl JL, et al. Carbamazepine-associated severe left ventricular dysfunction. J Toxicol Clin Toxicol 2000; 38(3): 339–42PubMedCrossRef
16.
Dalack GW, Roose SP, Glassman AH. Tricyclics and heart failure. Am J Psychiatry 1991 Nov; 148(11): 1601PubMed
17.
Terrence CF, Fromm G. Congestive heart failure during carbamazepine therapy. Ann Neurol 1980 Aug; 8(2): 200–1PubMedCrossRef
18.
Don Michael TA, Aiwazzadeh S. The effects of acute chloroquine poisoning with special reference to the heart. Am Heart J 1970 Jun; 79(6): 831–42PubMedCrossRef
19.
Marquardt K, Albertson TE. Treatment of hydroxychloroquine overdose. Am J Emerg Med 2001 Sep; 19(5): 420–4PubMedCrossRef
20.
Nord JE, Shah PK, Rinaldi RZ, et al. Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. Semin Arthritis Rheum 2004 Apr; 33(5): 336–51PubMedCrossRef
21.
Baguet JP, Tremel F, Fabre M. Chloroquine cardiomyopathy with conduction disorders. Heart 1999 Feb; 81(2): 221–3PubMed
22.
Bleumink GS, Feenstra J, Sturkenboom MC, et al. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs 2003; 63(6): 525–34PubMedCrossRef
23.
Nichols GA, Hillier TA, Erbey JR, et al. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001 Sep; 24(9): 1614–9PubMedCrossRef
24.
Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet 2005 Oct 8; 366(9493): 1279–89PubMedCrossRef
25.
Scheen AJ. Combined thiazolidinedione-insulin therapy: should we be concerned about safety? Drug Saf 2004; 27(12): 841–56PubMedCrossRef
26.
Kermani A, Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc 2003 Sep; 78(9): 1088–91PubMedCrossRef
27.
Dargie HJ, Hildebrandt PR, Riegger GA, et al. Baseline B-type natriuretic peptide identifies patients with type 2 Diabetes and class II/III Heart failure at risk of fluid retention when treated with rosiglitazone. ACC Scientific Session; 2005 Mar 6; Orlando (FL)
28.
Deswal A, Bozkurt B, Seta Y, et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999 Jun 29; 99(25): 3224–6PubMedCrossRef
29.
Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003 Jul 1; 107(25): 3133–40PubMedCrossRef
30.
Hyrich KL, Silman AJ, Watson KD, et al. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 2004 Dec; 63(12): 1538–43PubMedCrossRef
31.
Kobayashi T, Sato Y, Hasegawa Y, et al. Multiple myeloma complicated by congestive heart failure following first administration of recombinant alpha-interferon. Intern Med 1992 Jul; 31(7): 936–40PubMedCrossRef
32.
Sonnenblick M, Rosin A. Cardiotoxicity of interferon: a review of 44 cases. Chest 1991 Mar; 99(3): 557–61PubMedCrossRef
33.
Du Bois JS, Udelson JE, Atkins MB. Severe reversible global and regional ventricular dysfunction associated with high-dose interleukin-2 immunotherapy. J Immunother Emphasis Tumor Immunol 1995 Aug; 18(2): 119–23PubMedCrossRef
34.
Goel M, Flaherty L, Lavine S, et al. Reversible cardiomyopathy after high-dose interleukin-2 therapy. J Immunother 1992 Apr; 11(3): 225–9PubMedCrossRef
35.
Chew CY, Hecht HS, Collett JT, et al. Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease. Am J Cardiol 1981 Apr; 47(4): 917–22PubMedCrossRef
36.
Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee and the Multicenter Diltiazem Postinfarction Research Group. Circulation 1991 Jan; 83(1): 52–60PubMedCrossRef
37.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002 Dec 18; 288(23): 2981–97CrossRef
38.
39.
40.
Guidelines Committee. 2003 European Society of Hypertension — European Society of Cardiology guidelines for the treatment of arterial hypertension. J Hypertens 2003; 21(6): 1011–53CrossRef
41.
Coughlin SS, Metayer C, McCarthy EP, et al. Respiratory illness, beta-agonists, and risk of idiopathic dilated cardiomyopathy. The Washington, DC, Dilated Cardiomyopathy Study. Am J Epidemiol 1995 Aug 15; 142(4): 395–403PubMed
42.
Au DH, Udris EM, Curtis JR, et al. Association between chronic heart failure and inhaled beta-2-adrenoceptor agonists. Am Heart J 2004 Nov; 148(5): 915–20PubMedCrossRef
43.
Libretto SE. A review of the toxicology of salbutamol (albuterol). Arch Toxicol 1994; 68(4): 213–6PubMedCrossRef
44.
Cazzola M, Matera MG, Donner CF. Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs 2005; 65(12): 1595–610PubMedCrossRef
45.
Maschio G. Erythropoietin and systemic hypertension. Nephrol Dial Transplant 1995; 10 Suppl. 2: 74–9PubMed
46.
Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003 Jan 21; 107(2): 294–9PubMedCrossRef
47.
Smith KJ, Bleyer AJ, Little WC, et al. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003 Sep 1; 59(3): 538–48PubMedCrossRef
48.
Taler SJ, Textor SC, Canzanello VJ, et al. Cyclosporin-induced hypertension: incidence, pathogenesis and management. Drug Saf 1999 May; 20(5): 437–49PubMedCrossRef
49.
Bantle JP, Boudreau RJ, Ferris TF. Suppression of plasma renin activity by cyclosporine. Am J Med 1987 Jul; 83(1): 59–64PubMedCrossRef
50.
Bartorelli A, Rimondini A. Severe hypertension in childhood due to prolonged skin application of a mineralocorticoid ointment. Hypertension 1984 Jul–Aug; 6(4): 586–8PubMedCrossRef
51.
Mantero F, Armanini D, Opocher G, et al. Mineralocorticoid hypertension due to a nasal spray containing 9 alpha-fluoroprednisolone. Am J Med 1981 Sep; 71(3): 352–7PubMedCrossRef
52.
Whitworth JA. Mechanisms of glucocorticoid-induced hypertension. Kidney Int 1987 May; 31(5): 1213–24PubMedCrossRef
53.
Whitworth JA, Gordon D, Andrews J, et al. The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume. J Hypertens 1989 Jul; 7(7): 537–49PubMedCrossRef
54.
Saruta T, Saade GA, Kaplan NM. A possible mechanism for hypertension induced by oral contraceptives: diminished feedback suppression of renin release. Arch Intern Med 1970 Oct; 126(4): 621–6PubMedCrossRef
55.
Clezy TM, Foy BN, Hodge RL, et al. Oral contraceptives and hypertension: an epidemiological survey. Br Heart J 1972 Dec; 34(12): 1238–43PubMedCrossRef
56.
Khaw KT, Peart WS. Blood pressure and contraceptive use. Br Med J (Clin Res Ed) 1982; 285(6339): 403–7CrossRef
57.
Mulatero P, Morra di Cella S, Veglio F. Hypertension, genotype and oral contraceptives. Pharmacogenomics 2002 Jan; 3(1): 57–63PubMedCrossRef
58.
Woods JW. Oral contraceptives and hypertension. Hypertension 1988 Mar; 11 (3 Pt 2): 1 -5
59.
Chasan-Taber L, Willett WC, Manson JE, et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996 Aug 1; 94(3): 483–9PubMedCrossRef
60.
Wyeth Pharmaceuticals. Venlafaxine [package insert]. Philadelphia (PA): Wyeth Pharmaceuticals, 1999
61.
Johnson EM, Whyte E, Mulsant BH, et al. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am J Geriatr Psychiatry 2006 Sep; 14(9): 796–802PubMedCrossRef
62.
Allard P, Gram L, Timdahl K, et al. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram. Int J Geriatr Psychiatry 2004 Dec; 19(12): 1123–30PubMedCrossRef
63.
Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994 Aug 15; 121(4): 289–300PubMed
64.
Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993 Feb 22; 153(4): 477–84PubMedCrossRef
65.
Oates JA, FitzGerald GA, Branch RA, et al. Clinical implications of prostaglandin and thromboxane A2 formation (2). N Engl J Med 1988 Sep 22; 319(12): 761–7PubMedCrossRef
66.
67.
Bresalier RS, Sandler RS, Quan H, et al. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005 Mar 17; 352(11): 1092–102PubMedCrossRef
68.
Aldington S, Shirtcliffe P, Weatherall M, et al. Increased risk of cardiovascular events with parecoxib/valdecoxib: a systematic review and meta-analysis. N Z Med J 2005 Nov 25; 118(1226): U1755PubMed
69.
Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005 Mar 17; 352(11): 1081–91PubMedCrossRef
70.
Kearney PM, Baigent C, Godwin J, et al. Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Metaanalysis of randomised trials. BMJ 2006 Jun 3; 332(7553): 1302–8PubMedCrossRef
71.
World Health Organization. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre casecontrol study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346(8990): 1575–82
72.
World Health Organization. Cardiovascular disease and steroid hormone contraception: report of a WHO scientific group. WHO Technical Report Series, No. 877. Geneva: World Health Organization, 1998
73.
Wilson PW, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study. N Engl J Med 1985 Oct 24; 313(17): 1038–43PubMedCrossRef
74.
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002 Jul 17; 288(3): 321–33PubMedCrossRef
75.
Bath PM, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 2005 Feb 12; 330(7487): 342PubMedCrossRef
76.
Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003 Apr; 24(2): 183–217PubMedCrossRef
77.
Barbaro G. Increased access to the emergency department for coronary heart disease of HIV-infected patients receiving highly active antiretroviral therapy. Ann Emerg Med 2002 Nov; 40(5): 530–1PubMedCrossRef
78.
Rickerts V, Brodt H, Staszewski S, et al. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur J Med Res 2000 Aug 18; 5(8): 329–33PubMed
79.
Barbaro G, Barbarini G, Pellicelli AM. HIV-associated coronary arteritis in a patient with fatal myocardial infarction. N Engl J Med 2001 Jun 7; 344(23): 1799–800PubMedCrossRef
80.
Carr A, Samaras K, Chisholm DJ, et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyper-lipidaemia, and insulin resistance. Lancet 1998 Jun 20; 351(9119): 1881–3PubMedCrossRef
81.
Sattler FR, Qian D, Louie S, et al. Elevated blood pressure in subjects with lipodystrophy. AIDS 2001 Oct 19; 15(15): 2001–10PubMedCrossRef
82.
Witz M, Lehmann J, Korzets Z. Acute brachial artery thrombosis as the initial manifestation of human immunodeficiency virus infection. Am J Hematol 2000 Jun; 64(2): 137–9PubMedCrossRef
83.
Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998 Aug 27; 339(9): 584–90PubMedCrossRef
84.
Taylor JE, Henderson IS, Stewart WK, et al. Erythropoietin and spontaneous platelet aggregation in haemodialysis patients. Lancet 1991 Nov 30; 338(8779): 1361–2PubMedCrossRef
85.
Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002 Nov 26; 167(11): 1269–70PubMed
86.
87.
Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 2000 Oct 7; 356(9237): 1219–23PubMedCrossRef
88.
Parkin L, Skegg DC, Herbison GP, et al. Psychotropic drugs and fatal pulmonary embolism. Pharmacoepidemiol Drug Saf 2003 Dec; 12(8): 647–52PubMedCrossRef
89.
Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 2006 Apr 10; 166(7): 719–28PubMedCrossRef
90.
Paakkari I. Cardiotoxicity of new antihistamines and cisapride. Toxicol Lett 2002 Feb 28; 127(1–3): 279–84PubMedCrossRef
91.
Carlsson L, Amos GJ, Andersson B, et al. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? J Pharmacol Exp Ther 1997 Jul; 282(1): 220–7PubMed
92.
Davies AJ, Harindra V, McEwan A, et al. Cardiotoxic effect with convulsions in terfenadine overdose. BMJ 1989 Feb 4; 298(6669): 325PubMedCrossRef
93.
Simons FE, Kesselman MS, Giddins NG, et al. Astemizole-induced torsade de pointes. Lancet 1988 Sep 10; 2(8611): 624PubMedCrossRef
94.
Vitola J, Vukanovic J, Roden DM. Cisapride-induced torsades de pointes. J Cardiovasc Electrophysiol 1998 Oct; 9(10): 1109–13PubMedCrossRef
95.
Nattel S, Ranger S, Talajic M, et al. Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism. Am J Med 1990 Aug; 89(2): 235–8PubMedCrossRef
96.
Clark DW, Layton D, Wilton LV, et al. Profiles of hepatic and dysrhythmic cardiovascular events following use of fluoroquinolone antibacterials: experience from large cohorts from the Drug Safety Research Unit Prescription-Event Monitoring database. Drug Saf 2001; 24(15): 1143–54PubMedCrossRef
97.
Craven PC, Gremillion DH. Risk factors of ventricular fibrillation during rapid amphotericin B infusion. Antimicrob Agents Chemother 1985 May; 27(5): 868–71PubMedCrossRef
98.
Googe JH, Walterspiel JN. Arrhythmia caused by amphotericin B in a neonate. Pediatr Infect Dis J 1988 Jan; 7(1): 73PubMed
99.
Davis TM, Dembo LG, Kaye-Eddie SA, et al. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. Br J Clin Pharmacol 1996 Oct; 42(4): 415–21PubMedCrossRef
100.
Richter J, Burbach G, Hellgren U, et al. Aberrant atrioventricular conduction triggered by antimalarial prophylaxis with mefloquine. Lancet 1997 Jan 11; 349(9045): 101–2PubMedCrossRef
101.
Matson PA, Luby SP, Redd SC, et al. Cardiac effects of standard-dose halofantrine therapy. Am J Trop Med Hyg 1996 Mar; 54(3): 229–31PubMed
102.
Liebelt EL, Ulrich A, Francis PD, et al. Serial electrocardiogram changes in acute tricyclic antidepressant overdoses. Crit Care Med 1997 Oct; 25(10): 1721–6PubMedCrossRef
103.
104.
Buckley NA, Whyte IM, Dawson AH. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. J Toxicol Clin Toxicol 1995; 33(3): 199–204PubMedCrossRef
105.
Kiriike N, Maeda Y, Nishiwaki S, et al. Iatrogenic torsade de pointes induced by thioridazine. Biol Psychiatry 1987 Jan; 22(1): 99–103PubMedCrossRef
106.
Jackson T, Ditmanson L, Phibbs B. Torsade de pointes and low-dose oral haloperidol. Arch Intern Med 1997 Sep 22; 157(17): 2013–5PubMedCrossRef
107.
Zee-Cheng CS, Mueller CE, Seifert CF, et al. Haloperidol and torsades de pointes. Ann Intern Med 1985 Mar; 102(3): 418PubMed
108.
Chao CL, Chen WJ, Chen MF, et al. Torsade de pointes in a patient using usual dose of beta agonist therapy. Int J Cardiol 1996 Dec 13; 57(3): 295–6PubMedCrossRef
109.
Stewart AG, Waterhouse JC, Howard P. The QTc interval, autonomic neuropathy and mortality in hypoxaemic COPD. Respir Med 1995 Feb; 89(2): 79–84PubMedCrossRef
110.
Kerin NZ, Somberg J. Proarrhythmia: definition, risk factors, causes, treatment, and controversies. Am Heart J 1994 Sep; 128(3): 575–85PubMedCrossRef
111.
Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006 Mar 23; 440(7083): 463–9PubMedCrossRef
112.
Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences [published erratum appears in JAMA 1993 Apr 28; 269 (16): 2088]. JAMA 1993 Mar 24–31; 269(12): 1513–8PubMedCrossRef
113.
114.
Wehmeier PM, Heiser P, Remschmidt H. Myocarditis, pericarditis and cardiomyopathy in patients treated with clozapine. J Clin Pharm Ther 2005 Feb; 30(1): 91–6PubMedCrossRef
115.
Branik E, Nitschke M. Pericarditis and polyserositis as a side effect of clozapine in an adolescent girl. J Child Adolesc Psychopharmacol 2004; 14(2): 311–4PubMedCrossRef
116.
Ishikawa N, Imamura T, Nakajima K, et al. Acute pericarditis associated with 5-aminosalicylic acid (5-ASA) treatment for severe active ulcerative colitis. Intern Med 2001 Sep; 40(9): 901–4PubMedCrossRef
117.
Vayre F, Vayre-Oundjian L, Monsuez JJ. Pericarditis associated with longstanding mesalazine administration in a patient. Int J Cardiol 1999 Feb 28; 68(2): 243–5PubMedCrossRef
118.
Saura J, Aguilar M, Alio J. Pleural effusion and constrictive pericarditis secondary to bromocriptine treatment. Neurologia 1991 Nov; 6(9): 331–3PubMed
119.
Champagne S, Coste E, Peyriere H, et al. Chronic constrictive pericarditis induced by long-term bromocriptine therapy: report of two cases. Ann Pharmacother 1999 Oct; 33(10): 1050–4PubMedCrossRef
120.
Ling LH, Ahlskog JE, Munger TM, et al. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson’s disease. Mayo Clin Proc 1999 Apr; 74(4): 371–5PubMedCrossRef
121.
Townsend M, MacIver DH. Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson’s disease. Heart 2004 Aug; 90(8): e47PubMedCrossRef
122.
Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine [published erratum appears in N Engl J Med 1997 Dec 11; 337 (24): 1783]. N Engl J Med 1997 Aug 28; 337(9): 581–8PubMedCrossRef
123.
Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 2007 Jan 4; 356(1): 39–46PubMedCrossRef
124.
Dazzi H, Kaufmann K, Follath F. Anthracycline-induced acute cardiotoxicity in adults treated for leukaemia: analysis of the clinico-pathological aspects of documented acute anthracycline-induced cardiotoxicity in patients treated for acute leukaemia at the University Hospital of Zurich, Switzerland, between 1990 and 1996. Ann Oncol 2001 Jul; 12(7): 963–6PubMedCrossRef
125.
Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973 Aug; 32(2): 302–14PubMedCrossRef
126.
Sparano JA, Brown DL, Wolff AC. Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers. Drug Saf 2002; 25(5): 301–11PubMedCrossRef
127.
Saini J, Rich MW, Lyss AP. Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity: report of three cases. Ann Intern Med 1987 Jun; 106(6): 814–6PubMed
128.
Shaddy RE, Olsen SL, Bristow MR, et al. Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. Am Heart J 1995 Jan; 129(1): 197–9PubMedCrossRef
129.
Hjalmarson A, Waagstein F. The role of beta-blockers in the treatment of cardiomyopathy and ischaemic heart failure. Drugs 1994; 47 (Suppl. 4): 31–9, discussion 39–40PubMedCrossRef
130.
Arico M, Nespoli L, Pedroni E, et al. Heart transplantation in a child with doxorubicin-induced cardiomyopathy. N Engl J Med 1988 Nov 17; 319(20): 1353PubMed
131.
Luthy A, Furrer M, Waser M, et al. Orthotopic heart transplantation: an efficient treatment in a young boy with doxorubicin-induced cardiomyopathy. J Heart Lung Transplant 1992 Jul–Aug; 11 (4 Pt 1): 815–6PubMed
132.
Singal PK, Illiskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998 Sep 24; 339(13): 900–5PubMedCrossRef
133.
Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 1980 Jan; 65(1): 128–35PubMedCrossRef
134.
Shapira J, Gotfried M, Lishner M, et al. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen: a prospective randomized evaluation. Cancer 1990 Feb 15; 65(4): 870–3PubMedCrossRef
135.
Conklin KA. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integr Cancer Ther 2005 Jun; 4(2): 110–30PubMedCrossRef
136.
Curran CF, Narang PK, Reynolds RD. Toxicity profile of dexrazoxane (Zinecard, ICRF-187, ADR-529, NSC-169780), a modulator of doxorubicin cardiotoxicity. Integr Cancer Ther 1991 Dec; 18(4): 241–52
137.
Pouillart P. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines. Cancer Treat Rev 2004 Nov; 30(7): 643–50PubMedCrossRef
138.
Safra T, Muggia F, Jeffers S, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m 2. Ann Oncol 2000 Aug; 11(8): 1029–33PubMedCrossRef
139.
Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000 Apr; 22(4): 263–302PubMedCrossRef
140.
Suter TM, Cook-Bruns N, Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 2004 Jun; 13(3): 173–83PubMedCrossRef
141.
Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999 Sep; 17(9): 2639–48PubMed
142.
Seidman A, Hudis C, Perri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002 Mar 1; 20(5): 1215–21PubMedCrossRef
143.
Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005 Nov 1; 23(31): 7820–6PubMedCrossRef
144.
Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006 Sep 1; 24(25): 4107–15PubMedCrossRef
145.
Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004 Aug 21–27; 364(9435): 675–84PubMedCrossRef
146.
Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000 Nov 23; 343(21): 1520–8PubMedCrossRef
147.
Solomon SD, McMurray JJ, Pfeffer MA, et al. Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005 Mar 17; 352(11): 1071–80PubMedCrossRef
148.
Fosslien E. Cardiovascular complications of non-steroidal antiinflammatory drugs. Ann Clin Lab Sci 2005; 35(4): 347–85PubMed
149.
Krotz F, Schiele TM, Klauss V, et al. Selective COX-2 inhibitors and risk of myocardial infarction. J Vasc Res 2005 Jul–Aug; 42(4): 312–24PubMedCrossRef
150.
Silverstein FE, Faich G, Goldstein G, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000 Sep 13; 284(10): 1247–55PubMedCrossRef
151.
Cannon CP, Curtis SP, Bolognese JA, et al. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am Heart J 2006 Aug; 152(2): 237–45PubMedCrossRef
152.
Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia. Can J Psychiatry 1991; 36(4): 239–45PubMed
153.
Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005 Dec; 150(6): 1115–21PubMedCrossRef
154.
Liperoti R, Pedone C, Lapane KL, et al. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med 2005 Dec 12–26; 165(22): 2677–82PubMedCrossRef
155.
Vesterby A, Pedersen JH, Kaempe B, et al. Sudden death during treatment with clozapine (Leponex). Ugeskr Laeger 1980 Jan 14; 142(3): 170–1PubMed
156.
Merrill DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol 2005 Feb; 25(1): 32–41PubMedCrossRef
157.
Tanner MA, Culling W. Clozapine associated dilated cardiomyopathy. Postgrad Med J 2003 Jul; 79(933): 412–3PubMedCrossRef
158.
Gale CR, Martyn CN, Cooper C. Cognitive impairment and mortality in a cohort of elderly people. BMJ 1996 Mar 9; 312(7031): 608–11PubMedCrossRef
159.
Yavuz D, Deyneli O, Akpinar I, et al. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol 2003 Sep; 149(3): 187–93PubMedCrossRef
160.
Greenspan A, Eerdekens M, Mahmoud R. Is there an increased rate of adverse cardiovascular events with respiradone in patients with dementia? [abstract]. Int J Neuropsychopharmacol 2004; 7 Suppl. 1: S205
161.
Cavazzoni P, Young C, Polzer J. Incidence of cerebrovascular adverse events and mortality during anti-psychotic trials of elderly patients with dementia. Proceedings of the 44th Annual New Clinical Drug Evaluation Unit; 2004 Jun 1–4; Phoenix (AZ)
162.
Isbister GK, Bowe SJ, Dawson A, et al. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 2004; 42(3): 277–85PubMedCrossRef
163.
Ramasubbu R. Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. J Clin Psychiatry 2004 Dec; 65(12): 1642–53PubMedCrossRef
164.
165.
166.
Inman WHW, Vessey MP. Investigation of death from pulmonary, coronary and cerebral trhrombosis and embolus in women of child-bearing age. BMJ 1968; 2(5599): 193–6PubMedCrossRef
167.
Quehenberger P, Loner U, Kapiotis S, et al. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. J Thromb Haemost 1996 Nov; 76(5): 729–34
168.
Pabinger I, Schneider B. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. The GTH Study Group on Natural Inhibitors. J Thromb Haemost 1994 May; 71(5): 548–52
169.
Vandenbrouke JP, Bloemenkamp KW, Rosendaal FR, et al. Incidence of venous thromboembolism in users of combined oral contraceptives: risk is particularly high with first use of oral contraceptives. BMJ 2000 Jan 1; 320(7226): 57–8PubMedCrossRef
170.
Winkler UH. Blood coagulation and oral contraceptives: a critical review. Contraception 1998 Mar; 57(3): 203–9PubMedCrossRef
171.
Crook D, Godsland I. Safety evaluation of modern oral contraceptives: effects on lipoprotein and carbohydrate metabolism [published erratum appears in Contraception 1998 Jun; 57 (6): 420]. Contraception 1998 Mar; 57(3): 189–201PubMedCrossRef
172.
World Health Organization. Acute myocardial infarction and combinedoral contraceptives: results of an international multicentre case-controlstudy: WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1997; 349: 1202–9CrossRef
173.
Sidney S, Siscovick DS, Petitti DB, et al. Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies. Circulation 1998 Sep 15; 98(11): 1058–63PubMedCrossRef
174.
Farley TM, Meirik O, Collins J. Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks. Hum Reprod Update 1999 Nov–Dec; 5(6): 721–35PubMedCrossRef
175.
Chang CL, Donaghy M, Poulter N. Migraine and stroke in young women: case-control study. The World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. BMJ 1999 Jan 2; 318(7175): 13–8PubMedCrossRef
176.
Dunn N, Thorogood M, Faragher B, et al. Oral contraceptives and myocardial infarction: results of the MICA case-control study. BMJ 1999 Jun 12; 318(7198): 1579–83PubMedCrossRef
177.
Stampfer MJ, Willett WC, Colditz MJ, et al. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985 Oct 24; 313(17): 1044–9PubMedCrossRef
178.
Ross RK, Paganini-Hill A, Mack TM, et al. Menopausal oestrogen therapy and protection from death from ischaemic heart disease. Lancet 1981 Apr 18; 1(8225): 858–60PubMedCrossRef
179.
Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the nurses’ health study: a prospective, observational study. Ann Intern Med 2001 Jul 3; 135(1): 1–8PubMed
180.
Chilvers CE, Knibb RC, Armstrong SJ, et al. Post menopausal hormone replacement therapy and risk of acute myocardial infarction: a case control study of women in the East Midlands, UK. Eur Heart J 2003 Dec; 24(24): 2197–205PubMedCrossRef
181.
Bromley SE, de Vries CS, Thomas D, et al. Hormone replacement therapy and risk of acute myocardial infarction: a review of the literature. Drug Saf 2005; 28(6): 473–93PubMedCrossRef
182.
Goldfrank LR, Hoffman RS. The cardiovascular effects of cocaine. Ann Emerg Med 1991 Feb; 20(2): 165–75PubMedCrossRef
183.
Hollander JE, Hoffman RS. Cocaine-induced myocardial infarction: an analysis and review of the literature. J Emerg Med 1992 Mar–Apr; 10(2): 169–77PubMedCrossRef
184.
Mittleman MA, Mintzer D, Maclure M, et al. Triggering of myocardial infarction by cocaine. Circulation 1999 Jun 1; 99(21): 2737–41PubMedCrossRef
185.
Chokshi SK, Moore R, Pandian NG, et al. Reversible cardiomyopathy associated with cocaine intoxication. Ann Intern Med 1989 Dec 15; 111(12): 1039–40PubMed
186.
Isner JM, Chokshi SK. Cardiovascular complications of cocaine. Curr Probl Cardiol 1991 Feb; 16(2): 89–123PubMedCrossRef
187.
Virmani R, Robinowitz M, Smialek JE, et al. Cardiovascular effects of cocaine: an autopsy study of 40 patients. Am Heart J 1988 May; 115(5): 1068–76PubMedCrossRef
188.
Chambers HF, Morris DL, Tauber MG, et al. Cocaine use and the risk for endocarditis in intravenous drug users. Ann Intern Med 1987 Jun; 106(6): 833–6PubMed
189.
Meredith TJ, Ruprah M, Liddle A, et al. Diagnosis and treatment of acute poisoning with volatile substances. Hum Toxicol 1989 Jul; 8(4): 277–86PubMedCrossRef
190.
Ghuran A, Nolan J. Recreational drug misuse: issues for the cardiologist. Heart 2000 Jun; 83(6): 627–33PubMedCrossRef
191.
Eisenberg DM, Kessler RC, Foster C, et al. Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med 1993 Jan 28; 328(4): 246–52PubMedCrossRef
192.
Jaffe AM, Gephardt D, Courtemanche L. Poisoning due to ingestion of Veratrum viride (false hellebore). J Emerg Med 1990 Mar–Apr; 8(2): 161–7PubMedCrossRef
193.
The review of natural products. St Louis (MO): Facts and Comparisons, 2001
194.
Litovitz TL, Holm KC, Clancy C, et al. 1992 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 1993 Sep; 11(5): 494–555PubMedCrossRef
195.
Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000 Dec 21; 343(25): 1833–8PubMedCrossRef
196.
Kuczkowski KM. Herbal ecstasy: cardiovascular complications of khat chewing in pregnancy. Acta Anaesthesiol Belg 2005; 56(1): 19–21PubMed
197.
Naik SD, Freudenberger RS. Ephedra-associated cardiomyopathy. Ann Pharmacother 2004 Mar; 38(3): 400–3PubMedCrossRef
198.
Izzo AA, Di Carlo G, Borrelli F, et al. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol 2005 Jan; 98(1): 1–14PubMedCrossRef
199.
Food and Drugs Agency, USA. FDA warns public about Chinese diet pills containing fenfluramine. FDA release 2002 Aug 12. Rockville (MD): FDA, 2002
200.
Sullivan ML, Martinez CM, Gennis P, et al. The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis 1998 Jul–Aug; 41(1): 1–15PubMedCrossRef
201.
Urhausen A, Albers T, Kindermann W. Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? Heart 2004 May; 90(5): 496–501PubMedCrossRef
202.
Chin MH, Goldman L. Factors contributing to the hospitalization of patients with congestive heart failure. Am J Public Health 1997 Apr; 87(4): 643–8PubMedCrossRef
Metadata
Title
Drug-Induced Cardiovascular Disorders
Authors
Dr C. Aengus Murphy
Henry J. Dargie
Publication date
01-09-2007
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 9/2007
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200730090-00005

Other articles of this Issue 9/2007

Drug Safety 9/2007 Go to the issue

Current Opinion

Is There Still a Role for Aprotinin in Cardiac Surgery?

Original Research Article

Adverse Drug Event Detection in a Community Hospital Utilising Computerised Medication and Laboratory Data

Original Research Article

Clinical Pattern of Zileuton-Associated Liver Injury

Practical Drug Safety

Thiazolidinediones and their Fluid-Related Adverse Effects

Review Article

Safety Considerations with Bisphosphonates for the Treatment of Osteoporosis

Review Article

Benefit-Risk Assessment of Nesiritide in the Treatment of Acute Decompensated Heart Failure